← Back to headlines
Regeneron Anticipates $102 Million in Q1 Pre-Tax IPR&D Charges
Biotechnology company Regeneron Pharmaceuticals expects to incur approximately $102 million in pre-tax in-process research and development charges for the first quarter.
8 Apr, 11:32 — 8 Apr, 11:32
Sources
Showing 1 of 1 sources
Related Stories
Lionel Richie Hospitalized in ICU Following St. Louis Concert
38m ago
Anna Hazare admitted to Mumbai hospital's ICU with acute dehydration, kidney issue
8h ago
Ebola Outbreak in Democratic Republic of Congo Surpasses 6,000 Cases
10h ago
England Pharmacies to Offer Free Quick Cholesterol Screening Tests
18h ago